Anacetrapib - ≥98%, high purity , Cholesteryl ester transfer protein inhibitor, CAS No.875446-37-0, Cholesteryl ester transfer protein inhibitor

Item Number
A127068
Grouped product items
SKUSizeAvailabilityPrice Qty
A127068-5mg
5mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$98.90
A127068-10mg
10mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$157.90
A127068-50mg
50mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$454.90

Basic Description

SynonymsAnacetrapib | 875446-37-0 | MK-0859 | MK0859 | Anacetrapib (MK-0859) | (4s,5r)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one | P7T269PR6S | CHEMBL1800807 | (4S,5R)-5-(3,
Specifications & PurityMoligand™, ≥98%
Biochemical and Physiological MechanismsAnacetrapib is a potent and selective CETP inhibitor for rhCETP and C13S CETP mutants with IC50 of 7.9 nM and 11.8 nM, respectively.
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionCholesteryl ester transfer protein inhibitor
Product Description

Anacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure. Phase 3.
A potent and selective CETP inhibitor.

Product Properties

ALogP8.8

Associated Targets(Human)

CETP Tchem Cholesteryl ester transfer protein (12 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
KCNH2 Tclin HERG (29587 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CETP Tchem Cholesteryl ester transfer protein (2422 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NR1I2 Tchem Pregnane X receptor (6667 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Homo sapiens (32628 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCI-H295R (47 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Liver (3974 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Hdac6 Histone deacetylase 6 (222 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Cavia porcellus (23802 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Syrian golden hamster (1610 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hamster (598 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
rep Replicase polyprotein 1ab (378 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Plasma (328 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Serum (58 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Kidney (1278 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Muscle (539 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SARS-CoV-2 (38078 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Names and Identifiers

IUPAC Name (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(4-fluoro-2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4-methyl-1,3-oxazolidin-2-one
INCHI InChI=1S/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3/t15-,26-/m0/s1
InChi Key MZZLGJHLQGUVPN-HAWMADMCSA-N
Canonical SMILES CC1C(OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
Isomeric SMILES C[C@H]1[C@H](OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
PubChem CID 11556427
Molecular Weight 637.51

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Chemical and Physical Properties

Solubility127 mg/mL in DMSO <1 mg/mL in Water 127 mg/mL in Ethanol.

Related Documents

References

1. Smith CJ, Ali A, Hammond ML, Li H, Lu Z, Napolitano J, Taylor GE, Thompson CF, Anderson MS, Chen Y et al..  (2011)  Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib..  J Med Chem,  54  (13): (4880-95).  [PMID:21682257]
2. Gutstein DE, Krishna R, Johns D, Surks HK, Dansky HM, Shah S, Mitchel YB, Arena J, Wagner JA.  (2012)  Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction..  Clin Pharmacol Ther,  91  (1): (109-22).  [PMID:22130116]
3. Kastelein JJ, Besseling J, Shah S, Bergeron J, Langslet G, Hovingh GK, Al-Saady N, Koeijvoets M, Hunter J, Johnson-Levonas AO et al..  (2015)  Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study..  Lancet,  385  (9983): (2153-61).  [PMID:25743173]
4. No authors listed.  (2015)  Dyslipidaemia: Anacetrapib reduces LDL cholesterol in patients with heterozygous familial hypercholesterolaemia..  Nat Rev Cardiol,  12  (5): (261).  [PMID:25824513]
5. Millar JS, Reyes-Soffer G, Jumes P, Dunbar RL, deGoma EM, Baer AL, Karmally W, Donovan DS, Rafeek H, Pollan L et al..  (2015)  Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects..  J Clin Invest,  125  (6): (2510-2522).  [PMID:25961461]
6. Filippatos TD, Kei A, Elisaf MS.  (2017)  Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?.  Diseases,  (4): (589-97).  [PMID:28961179]
7. Ready JM.  (2021)  Toward a Best-in-Class Inhibitor of Cholesteryl Ester Transfer Protein (CETP)..  J Med Chem,  64  (18): (13212-13214).  [PMID:34498872]

Solution Calculators